It has also been proposed that MyD88 influences Ras-related cytoplasmic ERK1/2 levels, and that MyD88-dependent signaling enhances the expressions of genes that could contribute to breast cancer progression and genes previously associated with poor outcomes in breast cancer patients [81]. This evidence concerns the gene MAPK3 and breast carcinoma.